Golden Walk as Measure of Gait Rehabilitation in Parkinson's Disease

Sponsor
I.R.C.C.S. Fondazione Santa Lucia (Other)
Overall Status
Recruiting
CT.gov ID
NCT04706572
Collaborator
University of Roma La Sapienza (Other), Università degli studi di Roma Foro Italico (Other)
50
1
2
23.5
2.1

Study Details

Study Description

Brief Summary

Gait is specifically impaired in Parkinson's disease (PD). External auditory cue based on a binary rhythm tested in PD patients disappear when the stimulus is removed. Golden Ratio (GR)is intrinsic in the human gait, but in PD patients this GR has been found impaired. Aim of the study is the administration of an auditory external cue based on a personalized Golden Ratio-rhythm which could potentially assist people with PD to cope with the difficulties that they experience while walking, thus increasing their mobility and autonomy.

Condition or Disease Intervention/Treatment Phase
  • Other: Stimulation with external auditory bio-feedback
N/A

Detailed Description

Gait is specifically impaired in Parkinson's disease (PD). External auditory cue based on a binary rhythm has been successfully used in people with PD to improve their gait quality, but the beneficial effects disappear when the stimulus is removed. Recent evidences have shown that, in healthy subjects, the structure of walking relies on a number, called Golden Ratio (GR), based on a perfect proportion between different gait phases. While GR is known to be impaired in people with PD, there are few evidences that a GR-based auditory stimulus could support people with PD in counteracting gait alterations. As hypothesis, an auditory external cue based on a personalized GR-rhythm could assist people with PD to cope with the difficulties that they experience while walking, thus increasing their mobility and autonomy, and that the nature of this GR-rhythm allows to maintain the beneficial effects in time. Two personalized auditory rhythms (a binary rhythm and a GR-rhythm) will be alternatively administered to each participant (see diagram below). Patient-specific rhythms will administered by a user-friendly ad-hoc app for smartphone. Two assessments will be performed during these 24 weeks, to assess treatment efficacy. At the end of the 24th week, half of patients will continue with the GR-rhythm and, in a final assessment, we will see if the effect lasts over time.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Golden Walk- A Wearable Technology Assessment and Biofeedback for Gait Rehabilitation in Parkinson's Disease Patients
Actual Study Start Date :
Jun 15, 2020
Anticipated Primary Completion Date :
Jan 1, 2022
Anticipated Study Completion Date :
Jun 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Patients with Golden Rhythm

Administration of an external auditory cue based on Golden Rhythm

Other: Stimulation with external auditory bio-feedback
Administration of an external cue based on a personalized Golden Ratio -rhythm or a metronome-rhythm through an ad-hoc App for Smartphone

Placebo Comparator: Patients with Metronome

Administration of an external auditory cue based on metronome binary rhythm

Other: Stimulation with external auditory bio-feedback
Administration of an external cue based on a personalized Golden Ratio -rhythm or a metronome-rhythm through an ad-hoc App for Smartphone

Outcome Measures

Primary Outcome Measures

  1. Efficacy of Golden Ratio-rhythm on Gait walking speed [18 months]

    Changes in walking speed between baseline and end of the study

Secondary Outcome Measures

  1. Efficacy of Golden Ratio-rhythm on stride lenght [18 months]

    Changes in stride length between baseline and end of the study and between more and less affected side

  2. Efficacy of Golden Ratio-rhythm on toe clearance [18 months]

    Changes in toe clearance between baseline and end of the study and between more and less affected side

  3. Efficacy of Golden Ratio-rhythm on hMaxMalleoli [18 months]

    Changes in maximum Malleoli heigth between baseline and end of the study and between more and less affected side

  4. Efficacy of Golden Ratio-rhythm on stride to stance ratio [18 months]

    Changes in stride to stance ratio between baseline and end of the study and between more and less affected side

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • diagnosis of idiopathic PD, as proposed by the Brain Bank Criteria for PD, since at least 5 years

  • suffered from a rigid akinetic form of bilateral Parkinson's Disease (Hoehn and Yahr: 2-3), according to current criteria

  • to be on stable treatment regimen for at least the 3 months before the recruitment

  • Mini Mental State Examination score >24

  • Do not vary the pharmacological treatment during the entire duration of the study

  • Be tested in "ON" medication state

Exclusion Criteria:
  • inability to stand or walk without aids or supports

  • factors affecting gait such as hip replacement, musculoskeletal disorders, uncorrected vision or vestibular problems;

  • inability to follow instructions;

  • severe dysautonomia with marked hypotension, major depression, dementia, pregnancy, or cardiac pacemaker

Contacts and Locations

Locations

Site City State Country Postal Code
1 IRCCS Santa Lucia Rome Lazio Italy 00179

Sponsors and Collaborators

  • I.R.C.C.S. Fondazione Santa Lucia
  • University of Roma La Sapienza
  • Università degli studi di Roma Foro Italico

Investigators

  • Principal Investigator: Antonella Peppe, Fondazione Santa Lucia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Antonella Peppe, Principal Investigator, I.R.C.C.S. Fondazione Santa Lucia
ClinicalTrials.gov Identifier:
NCT04706572
Other Study ID Numbers:
  • HSantaLucia
First Posted:
Jan 13, 2021
Last Update Posted:
Jan 22, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Antonella Peppe, Principal Investigator, I.R.C.C.S. Fondazione Santa Lucia
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 22, 2021